Skip to main navigation
Skip to search
Skip to main content
UT MD Anderson Cancer Center Home
Help & FAQ
Link opens in a new tab
Search content at UT MD Anderson Cancer Center
Home
Profiles
Research units
Equipment
Research output
Activities
Prizes
Cetuximab combined with chemotherapy in non-small cell lung cancer
Anne S. Tsao
Thoracic Head & Neck Medical Oncology
Research output
:
Contribution to journal
›
Review article
›
peer-review
Overview
Fingerprint
Fingerprint
Dive into the research topics of 'Cetuximab combined with chemotherapy in non-small cell lung cancer'. Together they form a unique fingerprint.
Sort by
Weight
Alphabetically
Keyphrases
Chemotherapy
100%
Non-small Cell Lung Cancer (NSCLC)
100%
Cetuximab
100%
Monoclonal Antibody
25%
Metastasis
25%
Angiogenic Factors
25%
Head-and-neck Squamous Cell Carcinoma (HNSCC)
25%
Apoptosis
25%
Tumor Cells
25%
Colorectal Cancer
25%
U.S. Food
25%
Immune Response
25%
Cell Cycle Progression
25%
Platinum-based Chemotherapy
25%
Antibody-dependent Cellular Cytotoxicity
25%
IgG1
25%
Cell Manufacturing
25%
Ligand Binding
25%
Erbitux
25%
Metastatic Non-small Cell Lung Cancer
25%
Chemotherapy-naïve Patients
25%
Biomarker Research
25%
Clinical Decision-making
25%
Epidermal Growth Factor Receptor Inhibitors (EGFRI)
25%
Trial Results
25%
Pharmacology, Toxicology and Pharmaceutical Science
Non Small Cell Lung Cancer
100%
Cetuximab
100%
Chemotherapy Regimen
100%
Neoplasm
20%
Angiogenic Factor
20%
Head and Neck Squamous Cell Carcinoma
20%
Colorectal Carcinoma
20%
Monoclonal Antibody
20%
Cytotoxicity
20%
Epidermal Growth Factor Receptor
20%
Biological Marker
20%
Immunoglobulin G1
20%
Platinum
20%